Dyne Therapeutics Inc
DYN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.84B
Close$
$6.80
56% downside
Current Fair Value
56% downsideOvervalued by 56% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.84 Billion |
|---|---|
| Enterprise Value | $2.18 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.47 |
| Beta | 1.08 |
| Outstanding Shares | 165,451,388 |
Return
| Return on Equity | -73.97% |
|---|---|
| Return on Assets | -52.25% |
| Return on Invested Capital | -56.27% |
Valuation & Multiples
| P/E Ratio | -4.56 |
|---|---|
| PEG | -7.47 |
| Price to Sales | - |
| Price to Book Ratio | 3.86 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.23 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.75
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.2127▼ 203.47% |
|---|---|
| Total Calls | 45,600▲ 18.75% |
| Total Puts | 192,100▼ 19.92% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.23%▲ 2.40% |
|---|---|
| Total Invested | $4.26B▲ 25.10% |
| Investors Holding | 254▲ 18.00% |
ESG Score
No data
About Dyne Therapeutics Inc
47 employeesDyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.